Cambridge Investment Research Advisors, Inc. Outlook Therapeutics, Inc. Transaction History

Cambridge Investment Research Advisors, Inc.

  • $26 Billion
  • Q1 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2020

Oct 29, 2020
SELL
$0.61 - $1.6 $6,100 - $16,000
-10,000 Closed
0 $0
Q2 2020

Jul 27, 2020
BUY
$0.56 - $1.41 $5,600 - $14,100
10,000 New
10,000 $12,000

Others Institutions Holding OTLK

# of Institutions
6
Shares Held
66.9K
Call Options Held
0
Put Options Held
0
View Full List

About Outlook Therapeutics, Inc.

OTLK Quotes by TradingView
  • Ticker OTLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 226,144,992
  • Market Cap $1.72B
  • Description
  • Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...
More about OTLK
Track This Portfolio

Track Cambridge Investment Research Advisors, Inc. Portfolio

Follow Cambridge Investment Research Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email